Viking Therapeutics Inc (VKTX) - Total Assets
Based on the latest financial reports, Viking Therapeutics Inc (VKTX) holds total assets worth $715.73 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Viking Therapeutics Inc (VKTX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Viking Therapeutics Inc - Total Assets Trend (2013–2025)
This chart illustrates how Viking Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See VKTX total equity for net asset value and shareholders' equity analysis.
Viking Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Viking Therapeutics Inc's total assets of $715.73 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Viking Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VKTX company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Viking Therapeutics Inc's current assets represent 100.0% of total assets in 2025, an increase from 99.6% in 2013.
- Cash Position: Cash and equivalents constituted 23.2% of total assets in 2025, down from 99.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Viking Therapeutics Inc Competitors by Total Assets
Key competitors of Viking Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Viking Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.33 | 33.09 | 19.35 |
| Quick Ratio | 9.33 | 33.09 | 19.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $638.93 Million | $879.80 Million | $236.95 Million |
Viking Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Viking Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.24 |
| Latest Market Cap to Assets Ratio | 4.68 |
| Asset Growth Rate (YoY) | -21.2% |
| Total Assets | $715.73 Million |
| Market Capitalization | $3.35 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Viking Therapeutics Inc's assets at a significant premium (4.68x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Viking Therapeutics Inc's assets decreased by 21.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Viking Therapeutics Inc (2013–2025)
The table below shows the annual total assets of Viking Therapeutics Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $715.73 Million | -21.20% |
| 2024-12-31 | $908.32 Million | +146.50% |
| 2023-12-31 | $368.49 Million | +118.65% |
| 2022-12-31 | $168.53 Million | -20.00% |
| 2021-12-31 | $210.66 Million | -17.87% |
| 2020-12-31 | $256.50 Million | -9.76% |
| 2019-12-31 | $284.26 Million | -5.97% |
| 2018-12-31 | $302.31 Million | +1266.60% |
| 2017-12-31 | $22.12 Million | +52.19% |
| 2016-12-31 | $14.54 Million | -5.85% |
| 2015-12-31 | $15.44 Million | +407.34% |
| 2014-12-31 | $3.04 Million | +1586.94% |
| 2013-12-31 | $180.39K | -- |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more